https://www.aacr.org/patients-caregivers/progress-against-cancer/ziftomenib-approved-for-certain-acute-myeloid-leukemias/
Ziftomenib Approved for Certain Acute Myeloid Leukemias | Research | AACR
Dec 3, 2025 - The FDA approved the menin inhibitor ziftomenib to treat adults with relapsed or refractory acute myeloid leukemias harboring NPM1 mutations.
for certainziftomenibapprovedacutemyeloid
https://www.mountsinai.org/clinical-trials/first-in-human-study-of-ziftomenib-in-relapsed-refractory-acute-myeloid-leukemia
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Mount Sinai -...
https://medlineplus.gov/druginfo/meds/a626005.html
Ziftomenib: MedlinePlus Drug Information
Ziftomenib: learn about side effects, dosage, special precautions, and more on MedlinePlus
ziftomenibmedlineplusdruginformation